Tagged with Sanofi

Global Pharma companies no longer view digital as a “nice to have” add on, but as an integral part of their business, yet there are still quite a few hurdles to overcome. Insights from pharma industry digital transformation leaders. Industry is on a dedicated and focused journey to leverage data and…

Spain Sanofí’s general manager for Spain, Margarita Lopez Acosta, comments on the company’s “Play to Win” strategy, the presence of the French giant in Spain and the leading role of the country in clinical trials. She also explains possible solutions to the challenges around access to innovation in Spain.  Both the…

Italy Italy, Europe’s fourth largest pharma market at a size of EUR 23.446 billion, has a highly decentralised healthcare system, with the country’s 20 regions negotiating market access for medicines individually following central regulatory approval. This creates significant complexities for the representatives of Big Pharma looking to roll out their latest…

Global The pandemic era has demonstrated the value of innovation, from the mRNA vaccine breakthrough to the use of new technology. Speaking at the recent FT US Pharma and Biotech Summit Sanofi’s CEO Paul Hudson demonstrated that the company is not just riding the current wave but continuing to innovate on…

Europe Having moved early on a promising phase II monoclonal antibody, Almirall is inching closer to entering the Sanofi-dominated European market for eczema after posting, along with Eli Lilly, positive phase III results for Lebrikizumab. The Catalan company says it is on track for a 2023 launch on the continent; Lilly…

France The top ten pharma companies in France for 2021. Sanofi leads the pack with EUR 2.367 billion in turnover, followed by Servier (EUR 2.284 billion) and Janssen (EUR 1.175 billion).

Japan A roundup of the latest news from Japanese pharma, including Kirin’s USD 870 million investment in its healthcare and pharmaceuticals businesses over the next three years, Sanofi’s world-first approval for its Niemann-Pick types A/B and B medicine in Japan, and the prospect of domestically developed COVID-19 vaccines being rolled out…

UAE Fokion Sinis, Sanofi Vaccines’ General Manager for the Greater Gulf Multi Country Organisation, outlines some of the key impacts that the COVID-19 pandemic has had on the vaccine industry, the five ‘A’s of successful vaccination campaigns, and his ambitions for the future at a moment of great transformation for both…

Ukraine Russia’s invasion of Ukraine has been roundly condemned by the pharmaceutical industry and almost all Big Pharmas have pledged humanitarian support to Ukraine. However, not all companies have followed the lead of businesses in other industries in severing ties with Russia, citing the importance of continuing to supply essential medicines…

Global When British executive Paul Hudson joined French pharma Sanofi back in 2019, he was quick to launch a “play to win” strategy, shedding underperforming areas and doubling down on its stronger assets.   While the COVID-19 pandemic – and Sanofi’s failure to bring a vaccine to market thus far, despite…

Italy Italy is a key destination for global clinical trial programs with EUR 700 million invested in 2020 alone according to national industry association Farmindustria, bringing access to medicines, knowledge, skills, and economic benefits. Here, Italy country managers from some of the world’s leading pharma companies weigh in on the pros…

Italy Sanofi’s Country Lead, President & Managing Director for Italy Marcello Cattani discusses his career track and explains the company’s broad manufacturing footprint in the country – where Sanofi has four plants. In addition, he comments on the imminent changes to the Italian healthcare system and how the organization is transforming…